During third phase, the activated EGFL7/NOTCH signaling maintains low level of c-Myc expression and gradually counters killing effect of EGFR kinase inhibition, and cancer cells are transitioning to drug-tolerant persister cells. This evidence concerns the gene EGFL7 and cancer.